Granite Point Capital Management, L.P. Avenue Therapeutics, Inc. Transaction History

Granite Point Capital Management, L.P.

  • $0
  • Q3 2023

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 05, 2019
SELL
$2.1 - $5.6 $35,954 - $95,877
-17,121 Closed
0 $0
Q2 2018

Aug 13, 2018
BUY
$3.58 - $4.96 $61,293 - $84,920
17,121 New
17,121 $61,000

About AVENUE THERAPEUTICS, INC.

ATXI Quotes by TradingView
  • Ticker ATXI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 4,127,720
  • Market Cap $14.1M
  • Description
  • Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was in...
More about ATXI
Track This Portfolio

Track Granite Point Capital Management, L.P. Portfolio

Follow Granite Point Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Granite Point Capital Management, L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email